title: Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.
abstract: This study evaluates the neuroprotective properties of some voltage-sensitive sodium channel blockers in a model of focal ischaemia. After curative treatment (0.5 and 24.5 h after insult), well known voltage-sensitive sodium channel blockers, phenytoin (2 x 100 mg/kg i.p.), carbamazepine (2 x 50 mg/kg i.p.), lamotrigine (2 x 50 mg/kg i.p.) and RP 66055 (2 x 8 mg/kg i.p.) were found to protect rats against brain damage induced by occlusion of the middle cerebral artery, by 40%, 24%, 28% and 44% respectively. These compounds were also active in protecting both mice and rats against tonic convulsions induced by electroshock, Intraperitoneal ED50 values in mice and rats respectively were of 5.2 and 12.5 mg/kg for phenytoin, 8.4 and 3.6 mg/kg for carbamazepine, 4.4 and 3.1 mg/kg for lamotrigine, 3.9 and 0.22 mg/kg for RP 66055. In contrast, lifarizine was totally devoid of activity in these three tests. This study extends an accumulation of data in the literature pointing to a therapeutic potential for voltage-dependent sodium channel blockers which penetrate the blood brain barrier. Such compounds as phenytoin, carbamazepine, lamotrigine or RP 66055 may act at sodium channels to prevent depolarization, inhibit release of neurotransmitters such as glutamate and thus protects the cortex against cellular damage induced by focal ischaemia by both pre- and post-synaptic inhibition of abnormal neurotransmission.
authors.affiliation: Department of Biology, Rhône-Poulenc Rorer, Vitry, France.
authors.forename: J
authors.initials: J
authors.lastname: Rataud
authors.forename: F
authors.initials: F
authors.lastname: Debarnot
authors.forename: V
authors.initials: V
authors.lastname: Mary
authors.forename: J
authors.initials: J
authors.lastname: Pratt
authors.forename: J M
authors.initials: JM
authors.lastname: Stutzmann
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D002545:Brain Ischemia / Q000503:physiopathology*; D002220:Carbamazepine / Q000494:pharmacology; D002536:Cerebral Arteries / Q000502:physiology; D004594:Electrophysiology; D004597:Electroshock; D007093:Imidazoles / Q000494:pharmacology; D000077213:Lamotrigine; D008297:Male; D051379:Mice; D010672:Phenytoin / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D012640:Seizures / Q000503:physiopathology*; D015222:Sodium Channels / Q000187:drug effects* / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology; D014227:Triazines / Q000494:pharmacology
chemical_list: D000927:Anticonvulsants; D007093:Imidazoles; D010879:Piperazines; C089331:RP 66055; D015222:Sodium Channels; D013844:Thiazoles; D014227:Triazines; D002220:Carbamazepine; D010672:Phenytoin; C067927:lifarizine; D000077213:Lamotrigine